Effect of Tangshen Formula on phospholipids metabolism in diabetic nephropathy patients

Yaoxue Xuebao

Volumn 46, Issue 7, 2011, Pages 780-786

  Huang, Min ^a,b   Zhu, Chao ^a,b   Liang, Qiong Lin ^b   Li, Ping ^c   Li, Jing ^d   Wang, Yi Ming ^b   Luo, Guo An ^a,b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^d BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Diabetic nephropathy; Phospholipase A2; Phospholipids metabolism; Protein kinase C pathway; Tangshen Formula

Indexed keywords

BIOLOGICAL MARKER; HERBACEOUS AGENT; PHOSPHOLIPASE A2; PHOSPHOLIPID; PROTEIN KINASE C; TANGSHEN FORMULA; UNCLASSIFIED DRUG;

ALLOPATHY; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NONHUMAN; PHOSPHOLIPID METABOLISM; PLASMA; TIME OF FLIGHT MASS SPECTROMETRY;

DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; GLYCEROPHOSPHOLIPIDS; HUMANS; LYSOPHOSPHATIDYLCHOLINES; PHOSPHOLIPASES A2; PHOSPHOLIPIDS; PLANTS, MEDICINAL; PROTEIN KINASE C; SIGNAL TRANSDUCTION; SPHINGOMYELINS;

EID: 80052640783     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Tang L, Yang YS, Ji RY. Progress in studies on antidiabetic agents [J]. Acta Pharm Sin, 2001, 36: 711-715. (Pubitemid 33632004)
2. Li L. Progress in therapy of diabetes complicated with nephropathy [J]. Prac Pharm Clin Rem, 2005, 8: 3-5.
3. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy [J]. J Am Soc Nephrol, 2005, 16: S30-S33. (Pubitemid 41725079)
4. Mogensen CE. Microalbuminuria as a predictor of clinical diabetic nephropathy [J]. Kidney Int, 1987, 31: 673-689. (Pubitemid 17012586)
5. Li YY, Dong GY. The relationship between the advanced glycation ends products and the diabetes nephropathy [J]. Shandong Med J, 2004, 44: 15-16.
6. Susztak K, Raff AC, Schiffer M, et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy [J]. Diabetes, 2006, 55: 225-233. (Pubitemid 43343319)
7. Hansen HP, Tauber-Lassen E, Jensen BR, et al. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy [J]. Kidney Int, 2002, 62: 220-228. (Pubitemid 34754065)
8. Meier M, Kaiser T, Herrmann A, et al. Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis [J]. J Diabetes Complications, 2005, 19: 223-232. (Pubitemid 40910204)
9. Sugimoto H, Grahovac G, Zeisberg M, et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors [J]. Diabetes, 2007, 56: 1825-1833. (Pubitemid 47025452)
10. Han LD, Liang QL, Wang YM, et al. A new metabonomics method for simultaneous determination of EFAs and NEFAs in plasma using GC-MS and its application [J]. Chin Chem Lett, 2009, 20: 1103-1106.
11. Canani LH, Capp C, Ng DPK, et al. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes [J]. Diabetes, 2005, 54: 3326-3330. (Pubitemid 43334390)
12. Garman J, Dixon A, Maric C. Protective effects of omega-3 fatty acids in an animal model of diabetic nephropathy [J]. FASEB J, 2007, 21: 739.
13. Pang LQ, Liang QL, Wang YM, et al. Simultaneous determination and quantification of seven major phospholipid classes in human blood using normal-phase liquid chromatography coupled with electrospray mass spectrometry and the application in diabetes nephropathy [J]. J Chromatogr B, 2008, 869: 118-125.
14. 2 in rats kidneys with diabetic nephropathy [J]. J Nephrol Dialy Transplant, 2000, 9: 436-437.
15. Kanzaki T, Ishikawa Y, Morisaki N, et al. Abnormal metabolism of polyunsaturated fatty acids and phospholipids in diabetic glomeruli [J]. Lipids, 1987, 22: 704-710.
16. Jiang ZT, Liang QL, Luo GA, et al. HPLC-electrospray tandem mass spectrometry for simultaneous quantitation of eight plasma aminothiols: application to studies of diabetic nephropathy [J]. Talanta, 2009, 77: 1279-1284.
17. Xia JF, Liang QL, Hu P, et al. Correlations of six related purine metabolites and diabetic nephropathy in Chinese type 2 diabetic patients [J]. Clin Biochem, 2009, 42: 215-220.
18. Yamagishi SI, Fukami K, Ueda S, et al. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention [J]. Curr Drug Targets, 2007, 8: 952-959.
19. King GL, Das-Evciment N. Role of protein kinase C in diabetic complications [J]. Expert Rev Endocrinol Metabol, 2010, 5: 77-88.
20. Zhu C, Liang QL, Wei H, et al. Phospholipidomic identification of potential biomarkers of diabetic mellitus and diabetic nephropathy [EB/OL]. Amsterdam: Netherlands Metabolomics Centre, 2010 [2011-06-08]. http://www.metabolomics2010.com/.
21. Gao HJ, Li FL, Zhao YK. The research progress of treating diabetic nephropathy by traditional Chinese medicine [J]. Chin J Inf Tradit Chin Med, 2010, 17(Suppl.): 106-108.
22. Chen HY, Wang JH, Geng S. Protective effect of extract of Apocynum venetum on kidneys of streptozotocin-induced diabetic rats [J]. Acta Pharm Sin, 2010, 45: 26-30.
23. Li B, Zhu WL, Chen KX. Advances in the study of berberine and its derivatives [J]. Acta Pharm Sin, 2008, 43: 773-787.
24. Zhang HJ, Li P, Zhao JB, et al. Renal protective effect of Tangshen Formula in rats with diabetic nephropathy [J]. J Beijing Univ Tradit Chin Med, 2009, 32: 244-248.
25. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling [J]. J Lipid Res, 2009: S237-242.
26. Michel V, Yuan ZF, Ramsubir S, et al. Choline transport for phospholipid synthesis [J]. Exp Biol Med, 2006, 231: 490-504.
27. Han XL, Yang JY, Yang K, et al. Alterations in myocardial cardiolipin content and composition occur at the very earliest stages of diabetes: a shotgun lipidomics study [J]. Biochemistry, 2007, 46: 6417-6428. (Pubitemid 46842885)
28. Zhu C, Liang QL, Wang YM, et al. Effect of Tangshen Formula on phospholipids metabolism of OLETF rats [J]. Chem J Chin Univ, 2011, in press.
29. Larkins RG, Dunlop ME. The link between hyperglycemia and diabetic nephropathy [J]. Diabetologia, 1992, 35: 499-504.
30. Schleicher E, Nerlich A. The role of hyperglycemia in the development of diabetic complications [J]. Horm Metab Res, 1996, 28: 367-373. (Pubitemid 26290636)
31. Altmaier E, Ramsay SL, Graber A, et al. Bioinformatics analysis of targeted metabolomics-uncovering old and new tales of diabetic mice under medication [J]. Endocrinology, 2008, 149: 3478-3489. (Pubitemid 351919596)
32. Haus JM, Kashyap SR, Kasumov T, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance [J]. Diabetes, 2009, 58: 337-343.
33. Peng WH, Qu Q. A pharmacology research of Radix Astragali Mongolici in treating kidney diseases [J]. Chin J Integr Tradit Western Nephrol, 2001, 2: 614-616.
34. Li Y, Wu WQ, Zhang YM, et al. The effect of erigeron breviscapus on renal protein kinase C in diabetic rats [J]. Chin J Nephrol, 2000, 16: 89-92.
35. Cheng S, Tu QN, Lu FE. Effect of Panax notoginoside on the glomerular hyperfiltration and function of vascular endothelium in rats with experimental diabetes in its early stage [J]. Her Med, 2005, 24: 467-470.